Wendy Henninger
Nurse Practitioner · San Antonio, TXNPI 1710172838
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,506 and has fallen 69.7% since, to $456 in 2025. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $65.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$773
- Johnson & Johnson$488
- Karyopharm Therapeutics Inc.$423
- Astellas Pharma US Inc$416
- E.r. Squibb & Sons, L.L.C.$358
- Sanofi-aventis U.S. LLC$325
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,83292%
- Education$3508%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 9 | $773 |
| Johnson & Johnson | 4 | $488 |
| Karyopharm Therapeutics Inc. | 6 | $423 |
| Astellas Pharma US Inc | 6 | $416 |
| E.r. Squibb & Sons, L.L.C. | 3 | $358 |
| Sanofi-aventis U.S. LLC | 3 | $325 |
| Incyte Corporation | 4 | $291 |
| Daiichi Sankyo Inc. | 3 | $254 |
| Blueprint Medicines Corporation | 1 | $125 |
| Pfizer | 1 | $124 |
| Bristol Myers Squibb | 4 | $123 |
| Merck | 5 | $95 |
| Jazz Pharmaceuticals Inc. | 1 | $79 |
| AstraZeneca | 3 | $50 |
| Sanofi | 2 | $42 |
| Janssen Scientific Affairs, LLC | 1 | $42 |
| Legend Biotech USA Inc. | 2 | $41 |
| Adaptive Biotechnologies Corporation | 1 | $33 |
| GSK | 1 | $26 |
| Abbott | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Seagen Inc. | 1 | $17 |
| Teleflex LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,182 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 64 | $1,023 |
| Ondansetron OdtOndansetron | 25 | $265 |
| Famotidine | 23 | $171 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in San Antonio
- Corrie BerkSan Antonio$155K
- Sonja BruneSan Antonio$51K
- Laura GalvanSan Antonio$32K
- Eduardo GonzalezSan Antonio$32K
- Roberta RomeroSan Antonio$26K
- Christopher GarciaSan Antonio$21K
- Jennifer ZavalaSan Antonio$17K
- Amy RivasSan Antonio$17K
- Alexis WahlenSan Antonio$16K
- Cecilia DavisAustin$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.